Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase II Study of Temozolomide, Thalidomide and Celecoxib in Patients with Newly-Diagnosed Glioblastomas Multiforme in the Post-Radiation Setting

Phase II Study of Temozolomide, Thalidomide and Celecoxib in Patients with Newly-Diagnosed Glioblastomas Multiforme in the Post-Radiation Setting. Neuro-Oncology. 2004; Abstr. TA-64.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.